Target expression details
Target General Information | |||||
---|---|---|---|---|---|
Target ID | T83875 | ||||
Target Name | Monoamine oxidase type A | ||||
Synonyms | MAO-A; Monoamine oxidase; Monoamine oxidase A; MAOA | ||||
Target Type | Successful | ||||
Gene Name | MAOA | ||||
Biochemical Class | Oxidoreductases acting on CH-NH2 group of donors | ||||
UniProt ID | AOFA_HUMAN | ||||
Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals | |||||
Disease | Depression | ||||
Example drug | Isocarboxazid | Approved | [1], [2], [3] | ||
Tissue | Pre-frontal cortex | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.02 Z-score: -0.08 P-value: 4.12E-01 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
![]() |
|||||
Disease | Parkinson's disease | ||||
Example drug | Clorgyline | Approved | [4], [5], [6], [3] | ||
Tissue | Substantia nigra tissue | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.36 Z-score: -0.41 P-value: 6.93E-01 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
![]() |
|||||
Disease | Alzheimer's disease | ||||
Example drug | Ladostigil | Phase 2 | [7], [3] | ||
Tissue | Entorhinal cortex | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 0.05 Z-score: 0.10 P-value: 8.14E-01 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
![]() |
|||||
Disease | Vitiligo | ||||
Example drug | PIPERINE | Phase 1/2 | [8], [9], [3] | ||
Tissue | Skin | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.43 Z-score: -1.13 P-value: 1.20E-01 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
![]() |
|||||
Disease | Epilepsy | ||||
Example drug | CS-722 | Discontinued in Phase 2 | [10], [3] | ||
Tissue | Peritumoral cortex tissue | ||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of the persons with other diseases not directly affecting the tissue
![]() |
|||||
Target Gene Expression Profiles in Other Tissues of Healthy Individuals | |||||
![]() |
|||||
Reference | |||||
REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 011961. | ||||
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7204). | ||||
REF 3 | NCBI GEO: archive for functional genomics data sets--update. | ||||
REF 4 | Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6. Epub 2009 May 8. | ||||
REF 5 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6636). | ||||
REF 6 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
REF 7 | Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94. | ||||
REF 8 | ClinicalTrials.gov (NCT01383694) Effect Of Piperine In Patients With Oropharyngeal Dysphagia. U.S. National Institutes of Health. | ||||
REF 9 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2489). | ||||
REF 10 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003060) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.